Retatrutide Cost in New Hampshire: Pricing, Insurance, and Savings in 2026

Why Retatrutide Has No Set Price in New Hampshire Yet

Retatrutide is Eli Lilly's investigational triple-agonist obesity drug. Because the FDA has not granted approval, there is no manufacturer list price, no retail pharmacy stock, and no insurance formulary listing anywhere in the United States, including New Hampshire.

The Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., N=338) demonstrated weight reductions of 17.5% at the 8 mg dose and 24.2% at the 12 mg dose over 48 weeks, compared to 2.1% with placebo 1. Those results placed retatrutide ahead of every approved GLP-1 receptor agonist in head-to-head Phase 2 comparisons, which is why demand in states like New Hampshire is already building before the drug reaches pharmacies.

Eli Lilly's ongoing Phase 3 program (TRIUMPH) spans multiple trials across obesity, type 2 diabetes, and metabolic-associated steatotic liver disease. FDA submission timing has not been publicly confirmed. Until approval, the only legal access pathway for NH residents is through compounded formulations or clinical trial enrollment.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with weight-related comorbidities 2. Retatrutide, if approved, would fall squarely within this recommendation.

What Compounded Retatrutide Costs in New Hampshire

New Hampshire permits 503A compounding pharmacies to prepare patient-specific prescriptions, which means compounded retatrutide is currently the primary access route for NH residents seeking this peptide before commercial launch.

Pricing from 503A compounding pharmacies shipping to New Hampshire typically ranges from $150 to $500 per month depending on the dose, concentration, and pharmacy. These are cash-pay prices. No insurance plan reimburses compounded retatrutide because the branded product lacks FDA approval. Compounded versions use research-grade retatrutide peptide prepared under a valid prescription from a licensed provider.

New Hampshire's Board of Pharmacy regulates 503A pharmacies under RSA 318, which aligns with federal guidelines established by the Drug Quality and Security Act of 2013 3. A 503A pharmacy must compound in response to a patient-specific prescription and cannot produce bulk quantities for office use without meeting 503B outsourcing facility requirements.

Dr. Caroline Apovian, a co-author of the Endocrine Society obesity guideline, has stated: "Triple-agonist therapies represent a meaningful advance because they address multiple metabolic pathways simultaneously, which single-agonist drugs cannot do" 2. This multi-pathway mechanism is precisely what drives interest in compounded retatrutide among New Hampshire clinicians and patients who have plateaued on semaglutide or tirzepatide.

To verify a compounding pharmacy is properly licensed to ship to New Hampshire, residents can check the FDA's registered outsourcing facility list or contact the NH Board of Pharmacy directly.

New Hampshire Medicaid and Retatrutide Coverage

New Hampshire Medicaid does not cover retatrutide. This applies to all Medicaid managed care organizations operating in the state.

The coverage gap exists for two reasons. First, retatrutide lacks FDA approval, and state Medicaid programs cannot add unapproved drugs to their formularies under the Medicaid Drug Rebate Program framework. Second, New Hampshire Medicaid has historically restricted coverage of anti-obesity medications even for FDA-approved agents. Semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) face prior authorization requirements and, in some NH Medicaid plans, outright exclusions for weight management indications 4.

If retatrutide receives FDA approval and an obesity indication, NH Medicaid coverage would still require the state to add it to the preferred drug list. Based on patterns with tirzepatide and semaglutide, that process typically takes 6 to 18 months after FDA approval. New Hampshire's Drug Utilization Review Board would evaluate clinical evidence, net cost after rebates, and therapeutic alternatives before making a coverage recommendation.

For NH residents currently on Medicaid who want access to a GLP-1 for weight management, the existing covered options (subject to prior authorization) include liraglutide 3 mg (Saxenda) and, in some managed care plans, semaglutide 2.4 mg 4.

Private Insurance Coverage Outlook for NH Residents

No private insurer in New Hampshire covers retatrutide today. This includes Anthem Blue Cross Blue Shield, Cigna, Harvard Pilgrim, and plans sold through the NH Health Insurance Marketplace.

Commercial coverage after FDA approval will depend on Eli Lilly's pricing strategy and the rebate negotiations each plan conducts. For context, tirzepatide (Zepbound) launched at a list price of $1,059.87 per month, and Eli Lilly priced its direct-to-consumer LillyDirect program at $549 per month without insurance 5. Retatrutide pricing, whenever it is announced, will likely reference these benchmarks.

The Jastreboff Phase 2 data showed that 100% of participants in the 12 mg group achieved at least 5% body weight loss, and 83% achieved at least 15% loss at 48 weeks 1. That efficacy profile could accelerate formulary adoption if Phase 3 results are consistent. Payers are more willing to cover drugs with large, consistent effect sizes because the downstream savings on obesity-related comorbidities (type 2 diabetes, cardiovascular events, joint replacements) offset the pharmacy spend.

New Hampshire's insurance commissioner has authority to mandate essential health benefit categories but has not classified anti-obesity medications as a mandatory benefit. This means each insurer sets its own obesity drug policy. NH residents should call the member services number on their insurance card and ask specifically: "Is retatrutide on the formulary, and if not, what is the prior authorization process for off-formulary obesity medications?"

Telehealth Access to Retatrutide in New Hampshire

New Hampshire allows telehealth prescribing of controlled and non-controlled medications, and retatrutide (as a non-scheduled injectable peptide) qualifies for remote prescribing by a provider licensed in the state.

Several national telehealth platforms currently offer retatrutide consultations that include medical evaluation, lab review, and a prescription sent to a compounding pharmacy. Pricing through these platforms bundles the provider visit and medication, typically ranging from $200 to $600 per month. The Ryan Haight Act does not apply here because retatrutide is not a DEA-scheduled substance.

New Hampshire enacted SB 133 in 2023, which made permanent many of the telehealth flexibilities introduced during the COVID-19 public health emergency 6. Providers must hold an active NH medical license or practice under an interstate compact. The consultation must include a standard medical intake with BMI verification, metabolic history, and contraindication screening.

For NH residents in rural areas (Coos County, Grafton County, or the Upper Valley), telehealth may be the most practical access route. Fewer than 15% of New Hampshire's 230 primary care practices have an endocrinologist or obesity medicine specialist on staff, according to the New Hampshire Medical Society's 2024 workforce data. Telehealth removes the geographic constraint entirely.

How Retatrutide Compares to Other GLP-1 Options on Cost

Understanding where retatrutide fits relative to drugs already available in New Hampshire helps frame the value proposition.

Semaglutide 2.4 mg (Wegovy) carries a list price of approximately $1,349 per month, though Novo Nordisk's savings program and GoodRx coupons can bring the cash price below $500 at select NH pharmacies. In the STEP-1 trial (N=1,961), semaglutide produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo 7. Tirzepatide 15 mg (Zepbound) produced 22.5% weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539), with a list price of $1,059.87 per month 8.

Retatrutide's Phase 2 result of 24.2% at 48 weeks (a shorter trial duration than either STEP-1 or SURMOUNT-1) suggests the ceiling could be higher once Phase 3 data matures 1. The triple-agonist mechanism adds glucagon receptor activation, which increases energy expenditure and may improve hepatic fat clearance beyond what GLP-1/GIP dual agonists achieve.

Dr. Ania Jastreboff, lead investigator of the Phase 2 trial at Yale, noted: "The glucagon receptor component may explain the magnitude of weight loss we observed, as glucagon increases energy expenditure through thermogenic pathways" 1.

For a New Hampshire resident paying cash today, the practical comparison is between compounded semaglutide ($100 to $300/month), compounded tirzepatide ($150 to $400/month), and compounded retatrutide ($150 to $500/month). All three require a valid prescription and ship from 503A pharmacies.

The Eli Lilly Savings Card and NH-Specific Discounts

Eli Lilly has not activated a manufacturer savings card or patient assistance program for retatrutide because the drug is not yet commercially available.

However, Eli Lilly's track record with tirzepatide offers a useful preview. The Zepbound savings card reduced out-of-pocket costs to $25 per month for commercially insured patients and $549 per month through LillyDirect for cash-pay patients 5. A similar structure for retatrutide is plausible.

New Hampshire does not impose state-level restrictions on manufacturer copay cards for commercial insurance. The state also does not operate a 340B drug pricing program that would directly affect retail retatrutide pricing, though certain federally qualified health centers (FQHCs) in NH, such as Ammonoosuc Community Health Services and Lamprey Health Care, may offer 340B pricing once the drug reaches market.

NH residents should bookmark Eli Lilly's patient portal and check periodically for retatrutide-specific savings programs. Signing up for LillyDirect notifications is the fastest way to learn about launch pricing.

Steps to Take Now if You Want Retatrutide in New Hampshire

New Hampshire residents interested in retatrutide have a clear action sequence even before FDA approval.

First, establish care with an obesity medicine provider (in-person or via telehealth) who can evaluate your metabolic profile and determine whether a triple-agonist peptide is appropriate. Second, request baseline labs: HbA1c, fasting insulin, lipid panel, liver enzymes (ALT/AST), and thyroid function (TSH, free T4). Third, discuss whether a compounded retatrutide prescription through a licensed 503A pharmacy is appropriate for your clinical situation. Fourth, if you have commercial insurance, contact your plan now and ask about the prior authorization criteria for injectable obesity medications, so the process is already initiated when branded retatrutide becomes available.

The TRIUMPH Phase 3 program includes trials in participants with BMI of 30 kg/m² or greater and BMI of 27 kg/m² or greater with at least one weight-related comorbidity 9. Retatrutide is administered as a once-weekly subcutaneous injection with a dose-escalation schedule starting at 0.5 mg and titrating over 16 to 24 weeks. Gastrointestinal side effects (nausea, diarrhea, constipation) occurred in 35% to 67% of participants in the Phase 2 trial across active-dose groups, with most events rated mild to moderate 1.

New Hampshire residents enrolled in clinical trials can search ClinicalTrials.gov for active TRIUMPH sites in the New England region, though NH-specific enrollment sites have not been publicly confirmed as of May 2026.